Literature DB >> 10027576

Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes.

D M Neele1, E C de Wit, H M Princen.   

Abstract

Raised plasma lipoprotein(a) (lp(a)) concentrations have been reported in patients with Type I (insulin-dependent) diabetes mellitus, which were lowered by insulin therapy. To investigate the biochemical background of these changes, we studied the effect of insulin on apolipoprotein(a) (apo(a)) synthesis and mRNA levels in primary cultures of cynomolgus monkey hepatocytes. Low concentrations of insulin (10 nmol/l) had a small but significant decreasing effect (p < 0.046) on apolipoprotein(a) secretion (-16%). Maximum inhibition (-33%) was obtained after incubation for 72 h with 1000 nmol/l insulin. Apolipoprotein B-100 secretion was 30%-36% decreased when using 10-1000 nmol/l and no change was observed for the secretion of apolipoprotein A-1 and albumin which were measured as control proteins. Steady state apolipoprotein(a) mRNA concentrations paralleled the decrease in apolipoprotein(a) synthesis (-29% after incubating the cells for 48 h with 100 nmol/l insulin) indicating that the decreased synthesis is regulated at the (post)-transcriptional level. Concentrations of apolipoprotein B-100 and apolipoprotein A-1 mRNA were not changed after incubation with insulin. We conclude that high concentrations of insulin suppress apolipoprotein(a) synthesis in monkey hepatocytes at the (post)-transcriptional level. These data may provide an explanation for the increased plasma concentrations of lipoprotein(a) as found in patients with insulin dependent diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027576     DOI: 10.1007/s001250051110

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  22 in total

1.  Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors.

Authors:  Ming-Xing Xu; Chang Liu; Yong-Ming He; Xiang-Jun Yang; Xin Zhao
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.

Authors:  Lin Ding; An Song; Meng Dai; Min Xu; Wanwan Sun; Baihui Xu; Jichao Sun; Tiange Wang; Yu Xu; Jieli Lu; Weiqing Wang; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2015-02-03       Impact factor: 5.922

3.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

Review 4.  Pioglitazone.

Authors:  P S Gillies; C J Dunn
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

5.  Lipoprotein(a) and risk of type 2 diabetes.

Authors:  Samia Mora; Pia R Kamstrup; Nader Rifai; Børge G Nordestgaard; Julie E Buring; Paul M Ridker
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

6.  Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife: implications for the "timing hypothesis".

Authors:  MaryFran R Sowers; John Randolph; Mary Jannausch; Bill Lasley; Elizabeth Jackson; Daniel McConnell
Journal:  Arch Intern Med       Date:  2008-10-27

Review 7.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

8.  Lipoprotein(a) and cardiovascular disease in diabetic patients.

Authors:  Qibin Qi; Lu Qi
Journal:  Clin Lipidol       Date:  2012-08

Review 9.  Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.

Authors:  Sotirios Tsimikas
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-04       Impact factor: 3.243

10.  The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Authors:  Manjinder S Sandhu; Nita G Forouhi; Zheng Ye; Philip C Haycock; Deepti Gurdasani; Cristina Pomilla; S Matthijs Boekholdt; Sotirios Tsimikas; Kay-Tee Khaw; Nicholas J Wareham
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.